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Abstract
Chronic hepatitis C infection is a common cause of liver morbidity and mortality 
across the world, in part due to complications including cirrhosis and hepatocellular 
carcinoma. The advent of Direct-acting antiviral (DAA) therapy has the potential to 
change the outcome of HCV infection in the vast majority of patients. Unfortunately, 
the chronic nature of HCV infection means that many patients requiring direct-
acting antiviral (DAA) therapy have already developed compensated cirrhosis. 
This chapter reviews the importance of DAAs in the treatment of HCV infection, 
particularly in patients with existing compensated cirrhosis. Both efficacy and safety 
are discussed as essential endpoints of DAA therapy. Decompensated cirrhosis, treat-
ment failures, vitamin-D deficiency, HIV co-infection, and ethnic differences in the 
context of treatment response are also discussed in this chapter.
Keywords: direct-acting antivirals, chronic hepatitis C, hepatitis C virus, liver 
cirrhosis, treatment, adverse drug events
1. Introduction
Hepatitis C virus (HCV) is a leading cause of virologic morbidity and mortal-
ity, and afflicted individuals with HCV remain at high risk of cirrhosis, hepatic 
failure, and hepatocellular carcinoma [1]. The dormant nature of the Hepatitis 
C virus enables the virus to be both transmissible and silent. This may result in a 
more advanced initial presentation, as many patients are unaware of their positive 
infection status [2]. More advanced stages of HCV may involve cirrhosis, one of 
the most morbid outcomes after initial infection with HCV infection. As a result, 
many patients requiring HCV therapy are already cirrhotic and require a therapy 
which can effectively combat HCV in both non-cirrhotic and cirrhotic stages of the 
disease. The importance of treating the HCV virus in the compensated cirrhosis 
stage is paramount, to prevent the enhanced risk of worsening cirrhosis, decompen-
sation, hepatocellular carcinoma, and death [1].
The original treatment option in chronic HCV infection was interferon-based 
regimens. Interferon-based regimens were once the mainstay of therapy, but it has 
limited effectiveness in their ability to consistently induce a sustained virologic 
response (SVR) in chronic HCV at high enough rates to be a plausible solution for 
HCV [3]. Due to the infectious and chronic nature of hepatitis C, a more successful 
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therapy than interferon-based therapy was warranted to reduce the global burden 
of disease. In addition to its ineffectiveness, interferon-based regimens had numer-
ous side effects. The side effects are often severe and debilitating, which included 
bone marrow depression, neuropsychiatric symptoms, and flu-like symptoms. 
These side effects likely contributed to reduced patient adherence to interferon 
therapy [3].
The development of effective antiviral therapy for HCV infection was a difficult 
challenge. HCV exhibits some features which can make it difficult to treat. The 
HCV has a 9600-nucleotide positive sense RNA genome. The viral polymerase of 
HCV is unable to replicate at a high fidelity allowing for numerous errors. There is 
also a high viral replication rate. These two factors allow for the existence of diverse 
quasi-species, and in turn, the quasi-species makes both host immune response 
and pharmacological interventions less effective [2]. Fortunately, the new effective 
treatment was developed with the introduction of direct-acting antivirals (DAAs) 
for HCV infection. DAAs appear to meet the challenge of consistently inducing a 
high SVR in hepatitis C patients, including in patients who have already developed 
compensated cirrhosis.
2. The natural history of chronic hepatitis C and compensated cirrhosis
HCV is a blood-borne virus and will result in chronic infection in 55–85% of 
patients. Once the infection is chronic, patients are unlikely to have spontaneous 
resolution of their infection and are thus at risk of fibrosis, cirrhosis, and hepatocel-
lular carcinoma. Approximately 20–30% of patients with chronic HCV infection 
will develop cirrhosis [1]. There are numerous host factors in determining whether 
or not there will be a chronic infection, including IL-28B polymorphisms which may 
be associated with spontaneous resolution of the infection [2]. The development 
of cirrhosis at a cellular level is due to the virus inducing CD8+ T cell inflammation 
and necrosis, which is then followed by eventual healing via fibro-genesis pathways. 
This cycle of insult and healing can result in cirrhosis after 10–20 years of viral 
hepatitis [4].
Cirrhosis is a significant cause of detriment in the chronic HCV infection and 
ultimately can lead to the end stages of HCV infection, including decompensa-
tion, hepatocellular carcinoma (HCC), death, or the need for transplantation [5]. 
Decompensated cirrhotic patients HCV develop encephalopathy, ascites, or variceal 
bleed. Both variceal hemorrhage and HCC represent the fatal consequences of 
chronic HCV and cirrhosis [5]. Numerous studies done on DAAs and prevention of 
hepatocellular carcinoma indicate that DAA therapy does ultimately decrease the 
overall risk of HCC [6–8]. However, even with DAA therapy there still may be an 
increased risk of HCC in patients with treated HCV infection, so the exact benefit 
of DAAs on the reduction of HCC in patients who have existing HCV infection is 
unknown [9, 10]. Due to the uncertainty of the exact benefit of DAAs on HCC, 
patients with HCV and compensated cirrhosis should undergo HCC screenings, 
including those who have already completed a DAA regimen and achieved SVR.
DAA therapy is a relatively new concept and was designed to directly inhibit the 
viral lifecycle. In addition to the antiviral benefit, there is early evidence to indicate 
that DAA therapy is concurrently reducing HCV-associated manifestations includ-
ing cirrhosis and cirrhosis-related complications [6]. Evidence of DAA therapy’s 
protective benefit from HCV cirrhosis-related complications can be seen in trans-
plant databases. There is a relationship between DAA therapy and the decreased 
need for HCV-associated liver transplants [11]. This is of significant benefit, as a 
liver transplant represents the most expensive financial burden HCV can place on a 
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healthcare system, and by being able to mitigate this expense, DAAs may not only 
prove to be effective therapeutically but also economically [12].
While one of the most important goals of treating HCV is to prevent cirrhosis; a 
significant portion of HCV patients already have existing cirrhosis in need of DAA 
therapy. Furthermore, these patients are more likely to have DAA treatment failure 
versus their non-cirrhotic counterparts [13]. This makes DAA therapy of paramount 
significance for clinicians, in both preventing HCV cirrhosis and emphasizing the 
importance of selecting an appropriate DAA regimen in HCV patients with com-
pensated cirrhosis.
3. Direct-acting antiviral agents
DAAs were first approved by the Food and Drug Administration (FDA) in 2011 
and were used initially with the old standard of care interferon-based regimens 
[14]. DAAs can be classified into four different groups; protease inhibitors, poly-
merase inhibitors, NS5B inhibitors, and NS5A inhibits [14]. The primary mecha-
nism of DAAs is to directly inhibit the lifecycle replication of HCV virus. There 
are also specific methods of resistance that the HCV virus may develop, and it is 
essential to consider the possibility of resistance when starting HCV therapy [15].
There are numerous regimens available involving DAAs. The American 
Association for the Study of Liver disease (AASLD) have developed HCV guide-
lines to assist in selecting a particular DAA regimen based on variables including 
the genotype of HCV infection, treatment naïve status, existing compensated 
cirrhosis, decompensated cirrhosis, and co-infection with HIV (Table 1) [16]. 
DAA is typically 8 or 12 weeks depending on the indication given in the AASLD 
guidelines along with the regimen being given. Overall, SVR rates appear high 
with DAA regimens [13]. The benefits of DAAs can also be observed in histological 
Genotype Drug Treatment duration (weeks)
Genotype 1 Elbasvir/Grazoprevir 12
Glecaprevir/Pibrentasvir 12
Ledipasvir/Sofosbuvir 12
Sofosbuvir/Velpatasvir 12
Genotype 2 Glecaprevir/Pibrentasvir 12
Sofosbuvir/Velpatasvir 12
Genotype 3 Glecaprevir/Pibrentasvir 12
Sofosbuvir/Velpatasvir 12
Genotype 4 Elbasvir/Grazoprevir 12
Glecaprevir/Pibrentasvir 12
Ledipasvir/Sofosbuvir 12
Sofosbuvir/Velpatasvir 12
Genotype 5/6 Glecaprevir/Pibrentasvir 12
Ledipasvir/Sofosbuvir 12
Sofosbuvir/Velpatasvir 12
Table 1. 
DAA regimens for each HCV major genotype in the treatment of patients with compensated cirrhosis, according 
to current AASLD guidelines.
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studies. Patients who have achieved remission with DAAs show a lessened degree of 
inflammation on tissue specimen examination. Interestingly, there is no decrease in 
fibrosis noted at a histological level [17].
Successful DAA therapy is defined as a sustained virologic remission at 12 weeks 
(SVR12) post-treatment in the infected patient. The success of DAA therapy has 
a lot of variables, which is addressed in the AASLD guidelines. Corroborating an 
appropriate regimen based on a specific genotype, the presence of existing cir-
rhosis, HIV co-infection, treatment naivety, and treatment failure is all addressed 
in the AASLD guidelines [16]. In addition to the factors addressed in the AASLD 
guidelines, there appear to be some genetic examples influencing SVR in DAA 
therapy, include IL-28B polymorphisms, low-density lipid receptor genetic variants, 
vitamin D receptor, and bile salt export pump polymorphisms [18].
4. DAAs in the role of combating HCV as a public health problem
DAAs in conjunction with appropriate global health strategies provides us with 
the possibility to diminish HCV as a public health problem [19]. Analytical data col-
lected from a treat-all model indicate there is a cost-effective benefit to treating all 
HCV infected individuals with DAA regimens [20]. Urbanization is another crucial 
factor to consider as increased rates of urbanization may be associated with the risk 
of HCV [21]. Not all endemic areas with HCV are countries of means, so it remains 
necessary to consider the price of antiviral regimens and eliminate any economic 
barriers towards achieving comprehensive treatment response. One study analyz-
ing the cost of HCV treatment stated the current DAA price point appears to be 
affordable to treat most populations at an extensive level, similar to HIV. The same 
study concluded that genotype testing remains a significant cost until a consistent 
pan-genotypic DAA regimen can be developed [22]. The current DAA regimens and 
guidelines are contingent on knowing the genotype being treated. This is because 
much of the existing data in the literature shows a particular regimen’s treatment 
success rates as a function of the genotype being treated [16].
Public health programs should also be instituted alongside DAA therapy to help 
reduce the burden of HCV infection. In the United States, intravenous drug users 
are responsible for a new increase in HCV infections; before this rise, the incidence 
of HCV had been decreasing [1]. Being able to both reduce the rate of new infec-
tions while treat existing infections with DAA regimens would make the most logis-
tical sense in reducing the global burden of disease associated with HCV. In addition 
to the benefit of lowering HCV infections, the advent of DAAs could also reduce the 
global incidence of HCC as both hepatitis B and C are prominent identifiable risks 
for the development of HCC globally [23].
5. Hepatitis C genotypes
There are six major genotypes of HCV virus. There is a geographical component 
in HCV genotypes, as different regions of the world have a varying rate of the six 
different HCV genotypes. The information about HCV genotyping is significant, as 
it helps dictate therapy. The current AASLD guidelines rely primarily on genotype 
when assisting clinicians to select a particular DAA regimen. The genotype also 
provides pre-treatment success probabilities when selecting a DAA regimen for the 
achievement of SVR in patients with existing compensated cirrhosis. One study 
noted that HCV Genotype 1 patient with cirrhosis tend to have high SVR regardless 
of their cirrhosis status, but Genotype 3 patients have a more diminished response 
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and are therefore more difficult to treat in existing cirrhosis [24]. Ribavirin may be 
used as an adjunct with DAA regimens to help achieve SVR in patients with specific 
characteristics, including the genotype. Below are the major six genotypes of HCV, 
and the current AASLD guidelines for each one with an emphasis on the manage-
ment with compensated cirrhosis.
5.1 Genotype 1
Genotype 1 infection is the most common genotype globally, and it is also the 
most common genotype seen in developed countries [25]. Community-based stud-
ies conducted in the United States are often reflective of Genotype 1 infections as  
it is the predominant subtype in the United States, and Genotype 1 infections  
demonstrate a high overall SVR with DAA including in patients with existing  
cirrhosis [26].
5.1.1 Elbasvir/Grazoprevir
The C-WORTHY trial included patients that were both non-cirrhotic and 
existing compensated cirrhosis, with both groups being treated with Elbasvir/
Grazoprevir. The SVR reflected the success rate in both patients without cirrhosis 
and with compensated cirrhosis. The conclusion can be made that compensated 
cirrhosis is not a hindrance in the achievement of SVR in patients taking Elbasvir/
Grazoprevir [27]. The AASLD guidelines indicate 12 weeks of Elbasvir/Grazoprevir 
treatment is warranted in HCV Genotype 1 infections in both non-cirrhotic patients 
and in patients who have compensated cirrhosis [16].
5.1.2 Glecaprevir/Pibrentasvir
The EXPEDITION-1 study examined patients with compensated cirrhosis across 
genotypes 1, 2, 4, 5, and 6. Only genotype 3 was not represented among the six 
major genotypes. All 5 of the genotypes showed a high overall treatment response, 
with the genotype 1 patients with cirrhosis showing an SVR of 100% [28].
The CERTAIN-1 studied Japanese patients with genotype 1 infections, and also 
documented an excellent treatment response. The SVR remained high in patients 
with compensated cirrhosis, with all 38 cirrhotic patients achieving SVR [29]. The 
current AASLD guidelines mandate that non-cirrhotic, treatment naïve patients 
taking Glecaprevir/Pibrentasvir require 8 weeks of therapy, but the duration of 
therapy extends to 12 weeks with the presence of compensated cirrhosis [16].
5.1.3 Ledipasvir/Sofosbuvir
The ION-1 study showed high SVR rates in all treatment naïve patients with 
genotype 1 infection. The effect of cirrhosis on efficacy was difficult to determine, 
but there was no negative effect on the safety profile [30]. Ledipasvir/Sofosbuvir is 
an 8-week therapy in non-cirrhotic, non-black, non-HIV positive patients, but the 
presence of compensated cirrhosis changes the guidelines therapy to 12 weeks [16].
5.1.4 Sofosbuvir/Velpatasvir
Sofosbuvir/Velpatasvir is a 12-week regimen regardless of cirrhosis status 
[16]. The ASTRAL-1 examined patients who received Sofosbuvir/Velpatasvir for 
12 weeks across genotype 1, 2, 4, 5, 6 with genotype 3 not being represented. Across 
all 5 genotypes studied, there were 121 patients in ASTRAL-1 with compensated 
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cirrhosis. All but 1 achieved SVR (120/121), indicating a high success rate [31]. This 
may also help support the idea that Sofosbuvir/Velpatasvir could potentially be a 
pan-genotypic drug in compensated cirrhosis, as 5 of the six major genotypes were 
in this study.
5.2 Genotype 2 infection
Genotype 2 infection is most commonly seen in East Asia [25]. There are currently 
2 AASLD recommended therapies for treatment naive Genotype 2 infections [16].
5.2.1 Glecaprevir/Pibrentasvir
The EXPEDITION-1 trial examined genotype 2 patients, and similar to the 
genotype 1 patients, genotype 2 patients with compensated cirrhosis achieved SVR 
at a high rate of 100% with Glecaprevir/Pibrentasvir [28]. These findings were 
reproduced in the CERTAIN-1 trial in Japan, with all 18 genotype 2 patients with 
compensated cirrhosis achieving SVR without any adverse drug reactions [32].
5.2.2 Sofosbuvir/Velpatasvir
The Sofosbuvir/Velpatasvir regimen to combat genotype 2 infections was stud-
ied in the ASTRAL-1 and ASTRAL-2 studies. The results showed that Sofosbuvir/
Velpatasvir was effective at achieving SVR in genotype 2 infections (99%) and that 
SVR rates were not affected by cirrhosis [31].
5.3 Genotype 3 infection
After Genotype 1 infections, Genotype 3 infections are the most common type 
of HCV worldwide. Genotype 3 remains the most predominant type of HCV infec-
tion in South Asia [25]. Genotype 3 infections are a particular challenge when it 
comes to compensated cirrhosis. It is the second most common infection, but it does 
not respond well to first generation sofosbuvir-based regimens in the presence of 
cirrhosis. The ALLY-3 trial, involving the daclatasvir/sofosbuvir showed a response 
rate of 96% in patients without any cirrhosis. However, among patients with exist-
ing compensated cirrhosis, the response rate plummeted to a mere 63% [33].
5.3.1 Glecaprevir/Pibrentasvir
The Surveyor II study showed that with 12 weeks of therapy, treatment response 
was observed in 98% of Genotype 3 treatment naïve patients who had compensated 
cirrhosis [34]. The AASLD guidelines call for an 8-week therapy in treatment naïve 
patients without cirrhosis, but the presence of cirrhosis extends the Glecaprevir/
Pibrentasvir therapy to 12 weeks.
5.3.2 Sofosbuvir/Velpatasvir
The ASTRAL-3 study showed a high overall SVR for genotype 3 patients tak-
ing Sofosbuvir/Velpatasvir. However, there was a reduction in SVR from 97% in 
patients with no cirrhosis down to 91% in patients with cirrhosis [35]. Although 
there was a decrease in efficacy due to the presence of cirrhosis, it was a far less 
drastic decrease when comparing the outcomes in Genotype 3 treatment with 
Daclatasvir/Sofosbuvir in the presence of cirrhosis [33]. The standard of treatment 
is 12 weeks, regardless of cirrhosis status [16].
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5.4 Genotype 4 infection
Genotype 4 infections are seen in Africa and the Middle East, with Egypt, in 
particular, shouldering a high rate of HCV genotype 4 infections [25]. The response 
rate in genotype 4 infections appears to be high in some real-world studies, regard-
less of cirrhosis status [36].
5.4.1 Elbasvir/Grazoprevir
The current AASLD guidelines recommend a 12-week therapy, regardless of 
whether or not there is existing cirrhosis.
5.4.2 Glecaprevir/Pibrentasvir
EXPEDITION-1 showed that Genotype 4 patients with compensated cirrhosis 
still had a high SVR [28]. The AASLD guidelines dictate an 8-week regimen in 
patients with no history of cirrhosis, but the Glecaprevir/Pibrentasvir regimen 
becomes 12 weeks within patients with compensated cirrhosis.
5.4.3 Ledipasvir/Sofosbuvir
One study examined the success rate of Ledipasvir/Sofosbuvir with Genotype 4 
infection; with all patients achieving SVR regardless of any underlying fibrosis or 
cirrhosis [37].
5.4.4 Sofosbuvir/Ledipasvir
ASTRAL-1 showed all patients with Sofosbuvir/Ledipasvir and a Genotype 
4 infection achieved SVR12 [31]. The population studied had both patients with 
compensated cirrhosis and without cirrhosis patients, but both groups had an SVR 
of 100%. The AASLD mandates a 12-week therapy as the recommended regimen 
regardless of cirrhosis status.
5.5 Genotype 5 and genotype 6 infection
The current AASLD guidelines have HCV genotype 5 and genotype 6 infections 
grouped, but they remain 2 distinct major genotypes of HCV infection. Genotype 5 
represents the least commonly observed genotype of the major HCV genotypes and 
is most commonly seen in Sub-Saharan Africa and East Africa. Genotype 6 infec-
tions are most commonly seen in East Asia [25].
5.5.1 Glecaprevir/Pibrentasvir
The EXPEDITION-1 trial showed that patients with compensated cirrhosis and 
both genotype 5 and genotype 6 infection achieved remission at high rates [28].
5.5.2 Ledipasvir/Sofosbuvir
Genotype 5 compensated cirrhosis patients had studied in one trial had a lower 
response rate than their non-cirrhotic counterparts [38]. However, there was just 
one non-responder in each group, with 8/9 cirrhotic patients achieving SVR (89%) 
and 31/32 patients without cirrhosis achieving SVR (97%). Both non-responders 
had an IL-28B polymorphism.
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5.5.3 Sofosbuvir/Velpatasvir
Overall SVR12 was observed in patients with Genotype 5 and Genotype 6 
infections at rates of 97% and 100%, respectively in ASTRAL-1. Compensated 
cirrhosis was included in both groups of patients, and across all 5 genotypes (1, 2, 4, 
5, 6) studied in ASTRAL-1, 120/121 (99%) of patients with compensated cirrhosis 
achieved SVR [31].
6. Decompensated cirrhosis and direct acting anti-viral therapy
Patients with cirrhosis are at risk of hepatic decompensation, which includes 
ascites, encephalopathy, spontaneous bacterial peritonitis and variceal bleed [1]. 
The development of any one of these features represents increase mortality, and 
decompensation represents an end stage of HCV infection, with patients having a 
5-year survival rate of 51% [39]. Decompensation also remains an independent risk 
factor for the development of HCC [40].
Selecting an appropriate DAA therapy in patients with compensated cirrhosis is 
therefore important, as it may help to avoid the morbidity and mortality associated 
with decompensated cirrhosis. There are a few DAA regimens which show benefit 
in patients who have decompensated cirrhosis.
Before DAAs, interferon-based regimens were the only option, and in particular, 
when discussing the decompensated population, interferon-based regimens were 
both ineffective and poorly tolerated [41].
The ALLY-1 study looked at the effects of Daclatasvir/Sofosbuvir along with 
ribavirin on patients with advanced cirrhosis, including decompensated cirrhosis 
across 5 of the 6 major HCV genotypes, with genotype 5 being the only one not 
represented [42]. They noted a high treatment response with Child-Pugh A or B cir-
rhosis (93%), but once progression to Child-Pugh C cirrhosis occurred, the efficacy 
of Daclatasvir/Sofosbuvir was significantly diminished with a treatment response 
of 56%.
ASTRAL-4 also demonstrated a diminished response to DAAs in decompensated 
cirrhosis. Among patients who received Sofosbuvir/Velpatasvir alone, the SVR was 
83%. The addition of ribavirin however improved the SVR to 94% [43].
The adjunct use of ribavirin therapy and extending the duration may also be 
indicated in the treatment of HCV with decompensation according to current 
AASLD guidelines. Insulin resistance and protein malnutrition are two associated 
risks with the development of decompensated cirrhosis, so clinicians should be 
aware and attempt to address these issues to prevent further worsening of HCV into 
decompensation [44].
7.  Direct-acting antivirals in HCV/HIV co-infected patients and 
compensated cirrhosis
The Human Immunodeficiency Virus (HIV) and Hepatitis C (HCV) are both 
blood-borne infections which share common risk factors with regards to routes 
of transmission. Intravenous drug users may be at risk of both infections, and 
intravenous drug users represent the most common cause of new HCV infections 
[1]. Co-infection with HCV and HIV also appears to alter the host immune system, 
with strong evidence of decreased natural killer cells [45]. Clinicians also must 
exercise caution as there remains a possibility of drug-drug interaction, including 
hepatotoxicity between Highly Active-Antiretroviral Therapy (HAART) and DAA 
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[2]. This is a stark contrast from interferon-based regimens, which both struggled to 
consistently induce SVR and had numerous patient discontinuations due to adverse 
events [46]. Daclatasvir/Sofosbuvir appears to have a high success across genotypes 
1–4 as observed in the ALLY-2 study; with the success of Daclatasvir/Sofosbuvir 
being possibly contingent on favorable pharmacokinetics when interacting with 
HAART in HIV treatment. The SVR rates remained high even in patients with 
compensated cirrhosis, with a reported SVR of 92% in co-infected and cirrhotic 
patients The SVR was low with 8 weeks of therapy, and to achieve SVR of 92% 
patients required 12 weeks of treatment [47]. Community-based literature involv-
ing reiterate the idea that there may be a slightly diminished response in the HCV/
HIV co-infected cohort in real-world studies [48].
8.  Direct-acting antivirals in substance abuse patients with pre-existing 
cirrhosis
Substance abuse is a noteworthy variable when discussing hepatitis C virus 
and cirrhosis. Intravenous drug use and contaminated needles are now the most 
common way in which new cases of hepatitis C are contracted [1]. As a result, it is 
important to target the most common cause of new infections to help reduce the 
spread of hepatitis C virus. The AASLD guidelines currently recommend annual 
testing for the HCV virus alongside counseling on measures to reduce HCV trans-
mission [16].
9. Direct-acting antivirals in the African-American population
The African-American population is an important population when it comes to 
chronic hepatitis C infection, as they have an infection rate three times higher than 
the non-Hispanic White population [49]. Interferon-based treats were less effective 
in African-Americans than other groups, so there is some historical significance 
in finding a consistently effective treatment [50]. Fortunately, DAAs appears to 
be effective in the African-American population with response rates being high 
and treatment not having a significant variation with a history of compensated 
cirrhosis [51, 52]. Ethnicity is a factor seen in the AASLD guidelines; for instance, 
patients who would otherwise need 8 weeks of Ledipasvir/Sofosbuvir would require 
12 weeks due to African-American ethnicity [16].
10. Association of vitamin D level and HCV treatment response
Vitamin D deficiency appears to be a marker of hepatic dysfunction in patients 
who have the chronic liver disease and may be predictive of decompensation and 
mortality [53]. Vitamin D also has some molecular implications in the development 
of HCV related HCC [54]. Vitamin D deficiency is also noted to be more likely in 
patients with cirrhosis versus non-cirrhotic counterparts; although the levels of 
pre-treatment vitamin D does not appear to significantly influence SVR [55].
11. Management of non-responders
The AASLD treats patients who have failed interferon-based therapy in the same 
group as DAA naïve patients. DAAs remain effective treatment in the vast majority 
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of patients with compensated cirrhosis. However, there remains a portion of the 
hepatitis C patient population who do not respond to DAA therapy. These patients 
pose a unique challenge.
The POLARIS-1 and POLARIS-4 trials involve patients who have failed DAA 
regimens across 4 genotypes (genotype 1, 2, 3, 4) and were given Sofosbuvir/
Velpatasvir/Voxilaprevir. POLARIS-1 had an SVR of 96% in patients taking 
for re-treatment, with a 99% success in patients with no cirrhosis and 93% 
in patients with compensated cirrhosis. POLARIS-4 had an SVR of 98% and 
did not differ based on cirrhosis status [56]. The regimen of Sofosbuvir/
Velpatasvir/Voxilaprevir appears to be an effective therapy in DAA treatment 
failures.
12. Safety and tolerability of direct-acting antivirals
The development of DAAs not only improved the efficacy of HCV treatment 
but also enhanced the safety and tolerability of HCV therapy. The improved safety 
profile and increased tolerability can be observed in both patients with and without 
compensated cirrhosis. It is important to continue documenting data on adverse 
events and DAAs, as DAA regimens are a novel concept and require continued 
monitoring.
12.1 Elbasvir/Grazoprevir
In the C-WORTHY study looking at Genotype 1 patients, both with and without 
cirrhosis, Elbasvir/Grazoprevir commonly cause asthenia (14%), fatigue (26%), 
and headache (23%). However, serious events were far less common, occurring in 
only 3% of patients [27].
12.2 Glecaprevir/Pibrentasvir
The EXPEDITION-1 study evaluated Glecaprevir/Pibrentasvir in compensated 
cirrhosis across all genotypes except for Genotype 3 and noted that adverse events 
occurred in 69% of patients, most commonly fatigue and headaches. Severe adverse 
reactions occurred in 8% of patients, but there was no evidence of a direct drug-
induced adverse event [28]. In Genotype 3 patients, either with cirrhosis or prior 
treatment history, treatment with Glecaprevir/Pibrentasvir was well tolerated with 
no serious adverse event attributable to the regimen; nor any discontinuations 
because of an adverse drug reaction [34].
12.3 Ledipasvir/Sofosbuvir
ION-1 examined Genotype 1 patients without cirrhosis and in patients with 
compensated cirrhosis. Fatigue, headache, insomnia, and nausea were commonly 
observed adverse events. However, the overall safety profile was excellent, with 
no patients discontinuing the study due to adverse events [30]. Another study 
involving Genotype 4 patients, both with compensated cirrhosis and no history of 
cirrhosis also showed that Ledipasvir/Sofosbuvir is well-tolerated, with no serious 
adverse events and no discontinuations noted [37]. Genotype 5 patients receiving 
Ledipasvir/Sofosbuvir commonly had mild symptoms including asthenia, fatigue, 
and headache. One patient had a serious adverse reaction, but that was judged to be 
unrelated to DAA therapy [38].
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12.4 Sofosbuvir/Daclatasvir
The ALLY-1 trial involved the use of sofosbuvir/daclatasvir and ribavirin in 
patients with advanced cirrhosis across all major genotypes. Few serious adverse 
events were noted in the study, none of which could be directly attributable as a 
consequence of a drug. Anemia is a common side effect of ribavirin [42].
12.5 Sofosbuvir/Velpatasvir
A large study involving genotypes 1, 2, 4, 5,6 and patients with both com-
pensated cirrhosis and no history of cirrhosis showed a good safety profile. Less 
than 1% of patients discontinued therapy due to adverse reactions. There was no 
significant difference between the placebo group and the experimental group when 
it came to adverse events. The most common adverse events noted were fatigue, 
headache, nasopharyngitis, and nausea [31]. Another study examining Genotype 3 
infections, 2% of patients had adverse events severe enough to cause discontinua-
tion. Common adverse events were fatigue, headache, insomnia, and nausea [35].
13. Summary
Direct-acting antivirals represent a breakthrough in the treatment of hepatitis 
C virus. It has the potential to reduce the global burden of disease caused by the 
natural hepatitis C history, including cirrhosis, decompensation, and hepatocel-
lular carcinoma. It may also reduce the economic burden of liver transplants. The 
patient’s with existing compensated cirrhosis remain at an elevated risk of numer-
ous other complications, so it is imperative to have an appropriate therapy to help 
mitigate poor patient outcomes. There are numerous options with the new DAA 
and being able to appropriately select a regimen will allow for optimal sustained 
virologic responses in patients with compensated cirrhosis. The AASLD guidelines 
provide an excellent tool to help dictate a therapy which is tailored to each patient 
and genotype. As more research is collected on this novel therapy, DAA regimens 
have the potential to improve on its already remarkable efficacy.
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